Sanara MedTech Announces First Sale of ALLOCYTE® Plus Advanced Viable Bone Matrix and Provides Other Product Updates
2023年10月10日 - 10:15PM
Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”)
(NASDAQ: SMTI), a medical technology company focused on developing
and commercializing transformative technologies to improve clinical
outcomes and reduce healthcare expenditures in the surgical, wound
and skincare markets, announced today the first sale of
ALLOCYTE
® Plus Advanced Viable Bone Matrix
(“ALLOCYTE Plus” or “ALLOCYTE+”).
ALLOCYTE Plus First Sale
As previously disclosed, in late Q3 2022, the
Company began to experience material supply issues related to its
ALLOCYTE® Advanced Cellular Bone Matrix
(“ALLOCYTE”) product line. The supply constraint was caused by
significant supplier limits on qualifying eligible donor tissue and
supplier necessity to subcontract all processing to secondary
suppliers. Sanara has expanded the ALLOCYTE product line with the
release of ALLOCYTE Plus, a human cells, tissues, and cellular and
tissue-based products equivalent, which is processed by an
alternative supplier with in-house processing capabilities,
affording greater control of product supply. ALLOCYTE Plus was
first sold by the Company on October 9, 2023. Sanara currently has
a sufficient supply to meet expected demand and has orders in place
to be able to regularly stock the product in the future.
BIASURGE™
Advanced Surgical Solution (“BIASURGE”)
Updates
The commercial launch for BIASURGE is scheduled
for November 2023. Initial manufacturing runs have been completed
and the product is currently being evaluated by clinical partners
prior to the scheduled launch.
Zach Fleming, Sanara’s CEO, stated, “A key
strategic goal of Sanara is to continue to grow sales while
diversifying our product mix. Both ALLOCYTE Plus and BIASURGE are
key products that we believe will help the Company achieve that
goal. We believe the ALLOCYTE stock out has significantly impacted
our sales growth since the fourth quarter of 2022. Beginning sales
of ALLOCYTE Plus will allow us to fill the demand from surgeons who
understand the efficacy and value proposition of this product.
BIASURGE is an efficacious product intended for mechanical
cleansing and removal of debris, including microorganisms, from
wounds that we believe could potentially be utilized in any
surgical procedure where our existing products are currently
utilized. Our 40 sales managers have been trained on BIASURGE and
we are currently rolling out our training program for ALLOCYTE
Plus.”
About Sanara MedTech Inc.
With a focus on improving patient outcomes
through evidence-based healing solutions, Sanara MedTech Inc.
markets, distributes and develops surgical, wound and skincare
products for use by physicians and clinicians in hospitals, clinics
and all post-acute care settings and offers wound care and
dermatology virtual consultation services via telemedicine.
Sanara’s products are primarily sold in the North American advanced
wound care and surgical tissue repair markets. Sanara markets and
distributes CellerateRX® Surgical Activated
Collagen®, FORTIFY TRG® Tissue
Repair Graft and FORTIFY FLOWABLE® Extracellular
Matrix as well as a portfolio of advanced biologic products
focusing on ACTIGEN™ Verified Inductive Bone Matrix,
ALLOCYTE® Plus Advanced Viable Bone Matrix,
BiFORM® Bioactive Moldable Matrix and
TEXAGEN® Amniotic Membrane Allograft to the
surgical market. In addition, the following products are sold in
the wound care market: BIAKŌS® Antimicrobial Skin
and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel,
BIAKŌS® Antimicrobial Skin and Wound Irrigation
Solution and HYCOL® Hydrolyzed Collagen. Sanara’s
pipeline also contains potentially transformative product
candidates for mitigation of opportunistic pathogens and biofilm,
wound re-epithelialization and closure, necrotic tissue debridement
and cell compatible substrates. The Company believes it has the
ability to drive its pipeline from concept to preclinical and
clinical development while meeting quality and regulatory
requirements. Sanara is constantly seeking long-term strategic
partnerships with a focus on products that improve outcomes at a
lower overall cost. In addition, Sanara is actively seeking to
expand within its six focus areas of wound and skin care for the
acute, post-acute, and surgical markets. The focus areas are
debridement, biofilm removal, hydrolyzed collagen, advanced
biologics, negative pressure wound therapy products and the oxygen
delivery system segment of the wound and skincare markets.
Information about Forward-Looking
Statements
The statements in this press release that do not
constitute historical facts are “forward-looking statements,”
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by terms such as “aims,” “anticipates,”
“believes,” “contemplates,” “continue,” “could,” “estimates,”
“expect,” “forecast,” “guidance,” “intend,” “may,” “plan,”
“possible,” “potential,” “predicts,” “preliminary,” “projects,”
“seeks,” “should,” “targets,” “will” or “would,” or the negatives
of these terms, variations of these terms or other similar
expressions. These forward-looking statements include, among
others, statements regarding our ability to market, sell and meet
the demand for ALLOCYTE Plus, the timing and expected benefits of
the commercial launch of BIASURGE, the development of new products,
the timing of commercialization of our products, the regulatory
approval process and expansion of the Company’s business in
telehealth and wound care. These items involve risks, contingencies
and uncertainties such as the extent of product demand, market and
customer acceptance, the effect of economic conditions,
competition, pricing, uncertainties associated with the development
and process for obtaining regulatory approval for new products, the
ability to consummate and integrate acquisitions, and other risks,
contingencies and uncertainties detailed in the Company’s SEC
filings, which could cause the Company’s actual operating results,
performance or business plans or prospects to differ materially
from those expressed in, or implied by these statements.
All forward-looking statements speak only as of
the date on which they are made, and the Company undertakes no
obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events, except as
required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor
Relations713-826-0524CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
Sanara MedTech (NASDAQ:SMTI)
過去 株価チャート
から 5 2024 まで 6 2024
Sanara MedTech (NASDAQ:SMTI)
過去 株価チャート
から 6 2023 まで 6 2024